FDA product code · Clinical toxicology

Hemagglutination Inhibition, Barbiturate

Name: FDA decisions, review times, recalls and adverse event reports for product code DLX
Creator: 510(k) Report

DLXClass II21 CFR 862.3150510(k) required0 decisions0 recalls

0 FDA decisions. No recall names this code.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026 Download the data (CSV)

FIG. A — Illustration, clinical toxicology panel

Twenty years of DLX at a glance: how often FDA decides these devices, how long 510(k) reviews take, how often they are recalled, and how many adverse event reports name the code.

FIG. 1 — DLX by year, 2007–2026Sources: FDA decision databases, recall and enforcement reports, MAUDE · Data through Oct 25, 2026

Planning a device in DLX? A 510(k) Report ranks candidate predicates in this code by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report

Related product codes

Other codes under 21 CFR 862.3150.

DJN Mercury Dithiazone, Colorimetry, Barbiturate DKX Thin Layer Chromatography, Barbiturate DIS Enzyme Immunoassay, Barbiturate PUY Test, Barbiturate, Employment And Insurance…PTH Test, Barbiturate, Over The Counter DKN Radioimmunoassay, Barbiturate KZY High Pressure Liquid Chromatography, Barbiturate DMF Gas Liquid Chromatography, Barbiturate